Maxim Group set a $18.00 price target on Cellular Biomedicine Group Inc (NASDAQ:CBMG) in a report issued on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
Cellular Biomedicine Group (NASDAQ:CBMG) opened at 9.75 on Tuesday. The firm’s market capitalization is $139.33 million. The stock’s 50 day moving average price is $11.01 and its 200-day moving average price is $12.24. Cellular Biomedicine Group has a one year low of $10.00 and a one year high of $16.39.
Cellular Biomedicine Group (NASDAQ:CBMG) last issued its earnings results on Tuesday, March 14th. The biotechnology company reported ($0.43) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.43). Cellular Biomedicine Group had a negative return on equity of 36.06% and a negative net margin of 2,272.04%. The company had revenue of $0.06 million during the quarter. On average, equities research analysts expect that Cellular Biomedicine Group will post ($1.85) EPS for the current fiscal year.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.